Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment

References

• Cohen JA, Rudick RA. Aspects of multiple sclerosis that relate to trial design and clinical management. In: Cohen JA, Rudick RA, eds. Multiple sclerosis therapeutics. Boca Raton, FL: Taylor & Francis, 2007. p 3-22
   Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance No 594. 2004. Economic Research Institute, Stockholm School of Economics. Stockholm, Sweden. http://swopec.hhs.se/hastef/papers/hastef0594.pdf. Accessed April 27, 2013
   Google Scholar
• Tsang BK, Macdonell R. Multiple sclerosis: diagnosis, management and prognosis. Aust Fam Physician 2011;40:948-55.
   Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-56
   PubMed Web of Science ®Google Scholar
• Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci 2007;256(Suppl 1):S14-S18
   PubMedGoogle Scholar
• Bennetto L, Burrow J, Sakai H, et al. The relationship between relapse, impairment and disability in multiple sclerosis. Mult Scler 2011;17:1218-24
   PubMed Web of Science ®Google Scholar
• Vercellino M, Romagnolo A, Mattioda A, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand 2009;119:126-30
   PubMed Web of Science ®Google Scholar
• Iuliano G, Napoletano R, Esposito A. Multiple sclerosis: relapses and timing of remissions. Eur Neurol 2008;59:44-8
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. [The natural history of multiple sclerosis]. Rev Prat 2006;56:1313-20
   PubMedGoogle Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-16
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006;108:327-32
   PubMed Web of Science ®Google Scholar
• Bejaoui K, Rolak LA. What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 2010;74:900-2
   PubMedGoogle Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11-e25
   PubMedGoogle Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
   PubMed Web of Science ®Google Scholar
• Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients’ benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol 2009;256:554-62
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC201004/. Accessed April 27, 2013
   PubMed Web of Science ®Google Scholar
• Morrow SA, Metz LM, Kremenchutzky M. High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci 2009;36:213-5
   Google Scholar
• Habek M, Barun B, Puretic Z, et al. Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Ther Apher Dial 2010;14:298-302
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004;63:2028-33
   PubMed Web of Science ®Google Scholar
• Pickin M, Cooper CL, Chater T, et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study—early results and lessons for the future. BMC Neurol 2009;9:1. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631506/pdf/1471-2377-9-1.pdf. Accessed April 27, 2013
   Google Scholar
• Newmann PJ, Chambers JD, Simon F, et al. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood) 2011;30:2329-37
   Google Scholar
• Multiple Sclerosis Trust. Risk-sharing scheme. 2012. Multiple Sclerosis Trust. Hertfordshire, UK. http://www.mstrust.org.uk/research/risksharingscheme/. Accessed April 27, 2013
   Google Scholar
• Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value Health 2009;12:838-45
   Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research. Health database information. 2012. International Society for Pharmacoeconomics and Outcomes Research. Lawrenceville, NJ. Optum Clinformatics Data Mart (aka Invision). http://www.ispor.org/DigestOfIntDB/Default.aspx?rcd=393. Accessed June 19, 2013.
   Google Scholar
• Huang EA, Zdon GS, Moore RJ, et al. The impact of publishing medical specialty society guidelines on subsequent adoption of best practices: a case study with type 2 diabetes. Int J Clin Pract 2010;64:558-61
   Google Scholar
• Rubino M, Summers KH, Puenpatom A, et al. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. J Manag Care Pharm 2011;17:367-76
   PubMed Web of Science ®Google Scholar
• Chan L, Shumway-Cook A, Yorkston KM, et al. Design and validation of a methodology using the International Classification of Diseases, 9th Revision, to identify secondary conditions in people with disabilities. Arch Phys Med Rehabil 2005;86:1065-9
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Briggs A, O’Hagan A, et al. Review of statistical methods for analyzing healthcare resources and costs. Health Econ 2011;20:897–916
   Google Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ 2012;15:601-9
   PubMedGoogle Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Sbardella E, Greco A, Stromillo ML, et al. Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult Scler 2013;19:411-7
   PubMed Web of Science ®Google Scholar
• Horakova D, Kalincik T, Dolezal O, et al. Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand 2012;126:390-7
   PubMed Web of Science ®Google Scholar
• Pollack A. Drug deals tie prices to how well patients do. New York: New York Times, 2009. http://www.nytimes.com/2009/04/23/business/23cigna.html?_r=0. Accessed June 22, 2013
   Google Scholar
• Garber AM, McClellan MB. Satisfaction guaranteed—“payment by results” for biologic agents. N Engl J Med 2007;357:1575-7
   PubMed Web of Science ®Google Scholar
• Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787922/pdf/bmj.b4677.pdf. Accessed April 27, 2013
   Google Scholar